Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of type 2 diabetes mellitus~Exclusion Criteria~* History of type 1 diabetes mellitus~* Has undergone a surgical procedure within the prior 4 weeks.~* Current participation in, or has participated, in another study with an investigational device or compound, with the prior 12 weeks, and/or is not willing to refrain from participating in any other study while participating in this study~* Hypersensitivity or contraindication to any sulfonylurea (e.g., glimepiride) medication~* Has been on an investigational or approved dipeptidyl peptidase-4 (DPP-4) inhibitor agent (e.g., sitagliptin, saxagliptin)~* Presence of human immunodeficiency virus (HIV)~* Current participation in a weight loss program or is receiving weight loss medication~* History of blood disorder, certain cancers, heart, liver or kidney disease~* Current or past use of recreational or illicit drugs, or a history of drug abuse or dependence, or increased alcohol consumption

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
- Glimepiride (Type: ACTIVE_COMPARATOR): Glimepiride 1-6 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).